International Journal of Neuropsychopharmacology
September 9, 2026
B Richardson, J O'Byrne, V Bruno et al.
Abstract Background Psychedelics induce altered states of consciousness (AOC) with profound perceptual, cognitive, and emotional shifts, often linked to positive therapeutic outcomes. Although serotonergic psychedelics such as psilocybin, LSD, and 5-MeO-DMT share receptor targets, they differ in behavioral and neural effects. How these compounds alter cortical dynamics relative to other...
International Journal of Neuropsychopharmacology
September 9, 2026
S Socolow, B Richardson, S Nasini et al.
Abstract Background Major depression (MD) is a prevalent and debilitating disorder, characterized by anhedonia, persistent low mood, and learned helplessness, affecting up to 21% of adults over a lifetime. Chronic stress is a major environmental contributor to MD, and preclinical models of chronic mild stress (CMS) allow investigation of its behavioral and neurobiological consequences....
International Journal of Neuropsychopharmacology
September 9, 2026
B Richardson, S Socolow, M Lopez-Canul et al.
Abstract Background Recent clinical trials show that 5-MeO-DMT produces rapid antidepressant effects, yet the receptor mechanisms underlying these outcomes remain incompletely defined. Although 5-MeO-DMT is a high-affinity agonist at multiple serotonergic receptors, the relative contribution of 5-HT1A and 5-HT2A receptor signaling to its antidepressant-like actions has not been causally...
International Journal of Neuropsychopharmacology
September 9, 2026
V Bruno, M Lopez-Canul, B Richardson et al.
Abstract Background Psilocybin has shown therapeutic potential for several neuropsychiatric disorders; however, concerns remain regarding its abuse liability and long-term neurobiological effects following repeated use. While acute psychedelic administration is generally considered to have low addictive potential, the consequences of repeated exposure on reward processing, withdrawal-related...